Genetic Polymorphisms in Cytokine and Adhesion Molecule Genes in Coronary Artery Disease

Both inflammation and genetics play an important role in the pathogenesis of atherosclerosis and coronary artery disease. Epidemiological studies have investigated the association between coronary artery disease (CAD) and gene polymorphisms of the inflammatory molecules tumor necrosis factors (TNF) α and β, transforming growth factors (TGF) β-1 and β-2, interleukin (IL)-1 and its receptor antagonist (IL-1ra), CD 14 (the receptor for lipopolysaccharide), P- and E-selectins, and platelet endothelial cell adhesion molecule (PECAM)-1.Current evidence suggests that the TNF polymorphisms explored so far are not linked to CAD. The majority of studies conducted showed no significant association between TGFβ-1 and coronary atherosclerosis, but the data currently available are somewhat controversial. Some polymorphisms may increase the risk of myocardial infarction (MI) within specific ethnic groups or in certain populations. The association between the IL-1 system and atherosclerosis is complex and may vary as a result of a number of factors, such as stage of disease, clinical phenotype, and possibly population characteristics.The E-selectin gene (SELE) Arg128, 98T, and Phe554 alleles may increase the risk of atherosclerosis, but not necessarily the risk of MI. This association seems to be more pronounced in younger patients. The PECAM1 Leu125Val and Ser563Asn polymorphisms may increase the risk of atherosclerosis but not necessarily of MI. This association may be especially important in patients with a low risk for developing atherosclerosis.Current data indicate that screening for CD14-260C/T genotypes is unlikely to be a useful tool for risk assessment and it remains unclear whether CD14 polymorphisms significantly increase the risk of MI.The associations between candidate gene polymorphisms and CAD are complex as a consequence of pleiotropy, variations with age, selection due to the high lethality of the disease, and interactions with other genes and environmental factors. Nonetheless, although the current data is preliminary and partly conflicting, it does provide some evidence that alterations in the genetics of the inflammatory system may modify the risk of CAD.

[1]  R. Cotran,et al.  Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells , 1984, The Journal of experimental medicine.

[2]  W. Fiers,et al.  Two distinct monokines, interleukin 1 and tumor necrosis factor, each independently induce biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cells. , 1986, Journal of immunology.

[3]  G. Nuki,et al.  Tumour necrosis factor in synovial exudates. , 1988, Annals of the rheumatic diseases.

[4]  N. Morling,et al.  Association between HLA‐DR2 and Production of Tumour Necrosis Factor α and Interleukin 1 by Mononuclear Cells Activated by Lipopolysaccharide , 1988, Scandinavian journal of immunology.

[5]  H. Mcdevitt,et al.  Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[6]  B. M. Greenwood,et al.  TNF concentration in fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria , 1990, The Lancet.

[7]  H. Friedman,et al.  Viral activation of the coagulation cascade: Molecular interactions at the surface of infected endothelial cells , 1990, Cell.

[8]  P. Newman,et al.  Structure of the human gene encoding granule membrane protein-140, a member of the selectin family of adhesion receptors for leukocytes. , 1990, The Journal of biological chemistry.

[9]  G. Duff,et al.  Interleukin 1: the first interleukin. , 1990, Immunology today.

[10]  C. Jongeneel,et al.  A polymorphic microsatellite in the tumor necrosis factor alpha promoter identifies an allele unique to the NZW mouse strain , 1990, The Journal of experimental medicine.

[11]  R. Ulevitch,et al.  CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. , 1990, Science.

[12]  C. Dinarello.  Interleukin-1 and interleukin-1 antagonism. , 1991, Blood.

[13]  C. Jacob,et al.  Tumor necrosis factor alpha in murine systemic lupus erythematosus disease models: implications for genetic predisposition and immune regulation. , 1991, Cytokine.

[14]  F. Luscinskas,et al.  Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules , 1991, The Journal of experimental medicine.

[15]  A. Blakemore,et al.  Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR product. , 1992, Human molecular genetics.

[16]  J. Isner,et al.  Expression of transforming growth factor-beta 1 is increased in human vascular restenosis lesions. , 1992, The Journal of clinical investigation.

[17]  P. Vassalli,et al.  The pathophysiology of tumor necrosis factors. , 1992, Annual review of immunology.

[18]  C. Jacob.  Tumor necrosis factor α in autoimmunity: pretty girl or old witch? , 1992 .

[19]  N. Hogg,et al.  Adhesion molecules in cell interactions. , 1993, Current opinion in immunology.

[20]  B. Beutler,et al.  Polymorphism of the mouse TNF-alpha locus: sequence studies of the 3'-untranslated region and first intron. , 1993, Gene.

[21]  M. French,et al.  Polymorphic MHC ancestral haplotypes affect the activity of tumour necrosis factor‐alpha , 1993, Clinical and experimental immunology.

[22]  F. Pociot,et al.  An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles , 1993, The Journal of experimental medicine.

[23]  R. Lawn,et al.  Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice , 1994, Nature.

[24]  G. Baumann,et al.  E-selectin polymorphism and atherosclerosis: an association study. , 1994, Human molecular genetics.

[25]  T. McCaffrey,et al.  Decreased type II/type I TGF-beta receptor ratio in cells derived from human atherosclerotic lesions. Conversion from an antiproliferative to profibrotic response to TGF-beta1. , 1995, The Journal of clinical investigation.

[26]  D Kromhout,et al.  Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. , 1995, JAMA.

[27]  F. Alexander,et al.  Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial , 1995, BMJ.

[28]  D. Grainger,et al.  Tamoxifen elevates transforming growth factor–β and suppresses diet–induced formation of lipid lesions in mouse aorta , 1995, Nature Medicine.

[29]  T. Ueno,et al.  Increased soluble form of P-selectin in patients with unstable angina. , 1995, Circulation.

[30]  M. Ernst,et al.  Endotoxin activates human vascular smooth muscle cells despite lack of expression of CD14 mRNA or endogenous membrane CD14 , 1995, Infection and immunity.

[31]  P. Klingler,et al.  Transforming growth factor-beta synthesis by human peritoneal mesothelial cells. Induction by interleukin-1. , 1996, The American journal of pathology.

[32]  W. Liao.  Endotoxin: possible roles in initiation and development of atherosclerosis. , 1996, The Journal of laboratory and clinical medicine.

[33]  D. Arveiler,et al.  Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure. The Etude Cas-Témoin de l'Infarctus du Myocarde (ECTIM) Study. , 1996, Hypertension.

[34]  C. Holt,et al.  Interleukin-1β in Coronary Arteries of Patients With Ischemic Heart Disease , 1996 .

[35]  P. N. Rao,et al.  The human PECAM1 gene maps to 17q23. , 1996, Genomics.

[36]  M. Korner,et al.  Injury models of the vascular endothelium: apoptosis and loss of thromboresistance induced by a viral protein. , 1996, Haemostasis.

[37]  H. Mcdevitt,et al.  Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[38]  T. McCaffrey,et al.  Genomic instability in the type II TGF-beta1 receptor gene in atherosclerotic and restenotic vascular cells. , 1997, The Journal of clinical investigation.

[39]  P. Libby,et al.  Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. , 1997, Circulation.

[40]  J. Gunn,et al.  Transforming growth factor-beta1 gene polymorphisms and coronary artery disease. , 1998, Clinical science.

[41]  Winkelmann,et al.  Tumour necrosis factor β alleles and hyperinsulinaemia in coronary artery disease , 1998 .

[42]  D. Arveiler,et al.  Polymorphisms of the tumour necrosis factor‐α gene, coronary heart disease and obesity , 1998, European journal of clinical investigation.

[43]  G. Cardew,et al.  Association of genetic polymorphisms in the ace, apoe, and tgfβ genes with early onset ischemic heart disease , 1998 .

[44]  M. Nieminen,et al.  Role of infection as a risk factor for atherosclerosis, myocardial infarction, and stroke. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[45]  W. Kannel,et al.  Overview of atherosclerosis. , 1998, Clinical therapeutics.

[46]  J. Massagué.  TGF-beta signal transduction. , 1998, Annual review of biochemistry.

[47]  D. Wilcken,et al.  A common polymorphism of the transforming growth factor-beta1 gene and coronary artery disease. , 1998, Clinical science.

[48]  D. Arveiler,et al.  The P-selectin gene is highly polymorphic: reduced frequency of the Pro715 allele carriers in patients with myocardial infarction. , 1998, Human molecular genetics.

[49]  A. Maseri,et al.  Allelic polymorphism of the interleukin-1 receptor antagonist gene in patients with acute or stable presentation of ischemic heart disease. , 1999, Cardiologia.

[50]  S. Ye,et al.  A PstI polymorphism detects the mutation of serine128 to arginine in CD 62E gene - a risk factor for coronary artery disease. , 1999, Journal of biomedical science.

[51]  R. Ross,et al.  Atherosclerosis is an inflammatory disease. , 1998, American heart journal.

[52]  P. Hasleton,et al.  Tumour necrosis factor alpha and the cardiovascular system: its role in cardiac allograft rejection and heart disease. , 1999, Cardiovascular research.

[53]  G. Baumann,et al.  Functional Characterization of Atherosclerosis-Associated Ser128Arg and Leu554Phe E-Selectin Mutations , 1999, Biological chemistry.

[54]  K. Wenzel,et al.  The homozygous combination of Leu125Val and Ser563Asn polymorphisms in the PECAM1 (CD31) gene is associated with early severe coronary heart disease , 1999, Human mutation.

[55]  P. Hasleton,et al.  TNF-alpha in acute cardiac transplant rejection. , 1999, Cytokines, cellular & molecular therapy.

[56]  Jianhui Zhu,et al.  Infection and atherosclerosis: emerging mechanistic paradigms. , 1999, Circulation.

[57]  M. Kostrzewa,et al.  A new promoter polymorphism in the gene of lipopolysaccharide receptor CD14 is associated with expired myocardial infarction in patients with low atherosclerotic risk profile. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[58]  P. Nihoyannopoulos,et al.  Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. , 1999, Circulation.

[59]  N. Camp,et al.  Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease. , 1999, Circulation.

[60]  T. McCaffrey,et al.  The expression of TGF-beta receptors in human atherosclerosis: evidence for acquired resistance to apoptosis due to receptor imbalance. , 1999, Journal of molecular and cellular cardiology.

[61]  G. Schmitz,et al.  C(-260)-->T polymorphism in the promoter of the CD14 monocyte receptor gene as a risk factor for myocardial infarction. , 1999, Circulation.

[62]  P. Gurbel,et al.  Soluble PECAM-1, but Not P-Selectin, Nor Osteonectin Identify Acute Myocardial Infarction in Patients Presenting with Chest Pain , 1999, Cardiology.

[63]  A. Gardemann,et al.  The Impact of the Glycoprotein Ia Collagen Receptor Subunit A1648G Gene Polymorphism on Coronary Artery Disease and Acute Myocardial Infarction , 2000, Thrombosis and Haemostasis.

[64]  P. Grant,et al.  Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. , 2000, Blood.

[65]  A. Kastrati,et al.  Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting. , 2000, Journal of the American College of Cardiology.

[66]  L. Iacoviello,et al.  Possible different involvement of interleukin-1 receptor antagonist gene polymorphism in coronary single vessel disease and myocardial infarction. , 2000, Circulation.

[67]  M. Zago,et al.  Gene polymorphisms in the TNF locus and the risk of myocardial infarction. , 2000, Thrombosis research.

[68]  C. Morrison,et al.  Polymorphisms of the P-selectin gene and risk of myocardial infarction in men and women in the ECTIM extension study , 2000, Heart.

[69]  S. Humphries,et al.  Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. , 2000, European heart journal.

[70]  K. Shimada,et al.  Common polymorphism in the promoter of the CD14 monocyte receptor gene is associated with acute myocardial infarction in Japanese men. , 2000, The American journal of cardiology.

[71]  A. Gardemann,et al.  No Evidence for the CD31 C/G Gene Polymorphism as an Independent Risk Factor of Coronary Heart Disease , 2000, Thrombosis and Haemostasis.

[72]  P. Hasleton,et al.  Tumor necrosis factor-alpha gene polymorphism and death due to acute cellular rejection in a subgroup of heart transplant recipients. , 2001, Human immunology.

[73]  U. Ikeda,et al.  Interleukin‐6 and acute coronary syndrome , 2001, Clinical cardiology.

[74]  A. Rumley,et al.  Interleukin-6 Gene −174G>C and −572G>C Promoter Polymorphisms Are Strong Predictors of Plasma Interleukin-6 Levels After Coronary Artery Bypass Surgery , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[75]  P. Ridker,et al.  A prospective evaluation of the CD14 C(-260)T gene polymorphism and the risk of myocardial infarction. , 2001, Atherosclerosis.

[76]  M. Perola,et al.  Polymorphisms within the tumor necrosis factor locus and prevalence of coronary artery disease in middle-aged men. , 2001, Atherosclerosis.

[77]  J. Auer,et al.  Serum neopterin and activity of coronary artery disease. , 2001, Heart disease.

[78]  A. Kastrati,et al.  Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction. , 2001, Atherosclerosis.

[79]  J. Auer,et al.  Interleukin-1 receptor antagonist gene polymorphism, infectious burden, and coronary artery disease. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[80]  M. Lathrop,et al.  Genotype at a promoter polymorphism of the interleukin-6 gene is associated with baseline levels of plasma C-reactive protein. , 2002, Cardiovascular research.

[81]  J. Auer,et al.  Immunopathogenesis of atherosclerosis. , 2002, Circulation.

[82]  J. Auer,et al.  Prognostic significance of immune activation after acute coronary syndromes. , 2002, Journal of the American College of Cardiology.

[83]  J. Auer,et al.  Letter to the EditorCytokine gene polymorphisms and development of CAD associated with CP infection , 2002 .

[84]  J. Auer,et al.  C-reactive protein and coronary artery disease. , 2002, Japanese heart journal.

[85]  J. Auer,et al.  Cytokine gene polymorphisms and development of CAD associated with CP infection. , 2002, Journal of the American College of Cardiology.

[86]  W. März,et al.  The interleukin-6 G(–174)C promoter polymorphism in the LURIC cohort: no association with plasma interleukin-6, coronary artery disease, and myocardial infarction , 2002, Journal of Molecular Medicine.

[87]  J. Auer,et al.  Relation of C-reactive protein levels to presence, extent, and severity of angiographic coronary artery disease. , 2002, Indian heart journal.

[88]  T. Verbeuren,et al.  Effect of NADPH oxidase inhibition on E-selectin expression induced by concomitant anoxia/reoxygenation and TNF-alpha. , 2002, Endothelium : journal of endothelial cell research.

[89]  I. Porto,et al.  Inflammatory gene polymorphisms and ischaemic heart disease: review of population association studies , 2002, Heart.

[90]  Jeffrey L. Anderson,et al.  Chronic infection and coronary artery disease. , 2003, Cardiology clinics.

[91]  K. Rohde,et al.  DMA polymorphisms in adhesion molecule genes — a new risk factor for early atherosclerosis , 2004, Human Genetics.

[92]  S. D'alfonso,et al.  A polymorphic variation in a putative regulation box of the TNFA promoter region , 2004, Immunogenetics.